ReviewKidney international reports2023
Uric Acid and Chronic Kidney Disease: Still More to Do.
Review in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07199205 (Hyperuricemia as a Predictor of Chronic Kidney Disease), which is not on this map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperuricemia as a Predictor of Chronic Kidney Disease (CKD) Progression in Prediabetic Patients
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Reno-protective effects of xanthine oxidase inhibitors in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis.Journal of nephrology · 2025Pooled it
- Pooled it
- Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.BMJ open diabetes research & care · 2024Pooled it
- Longitudinal serum uric acid trajectories and chronic kidney disease progression.Irish journal of medical science · 2026Article
- Association Between the Planetary Health Diet Index and Serum Uric Acid Levels and Incident Hyperuricemia: Findings From an Iranian Prospective Cohort Study.Food science & nutrition · 2026Article
- Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways.Journal of biochemical and molecular toxicology · 2026Article
- Uric Acid and Chronic Kidney Disease.Kidney medicine · 2026Review
- Development and validation of a risk models for gout in patients with diabetic kidney disease.BMC endocrine disorders · 2026Article
- Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and targeted intervention.Rheumatology international · 2026Review
- Association of serum uric acid with cardiovascular-kidney-metabolic syndrome in elderly populations: results from Chinese and US cohorts.Scientific reports · 2026Article
- Allopurinol has no effect on calcitriol or other CKD-MBD biomarkers: a randomized double-blind study.Journal of the Endocrine Society · 2026Article
- Accuracy and readability of LLM-generated responses for gout management: a benchmark study based on ACR guidelines.Clinical rheumatology · 2026Article
- Role of urate transporters in the kidneys and intestine in uric acid homeostasis.Kidney research and clinical practice · 2026Article
- Timing of urate-lowering therapy and risk of kidney failure and mortality in CKD: an application of the parametric G-formula.Clinical kidney journal · 2026Article
- Impact of hyperuricemia on cardiac events in stable coronary artery disease patients with or without renal dysfunction.Heart and vessels · 2026Article
- Occupational heat exposure and chronic kidney disease risk under climate warming: a retrospective cohort study of petrochemical workers with mechanistic insights.Environmental health : a global access science source · 2026Article
- Development of a portable label-free electrochemical sensor modified with AuNPs/g-CMikrochimica acta · 2026Article
- Association of uric acid-to-HDL cholesterol ratio and coronary atherosclerotic heart disease in patients with and without CKD.BMC cardiovascular disorders · 2026Article
- Effect of dotinurad versus febuxostat on the one-year eGFR slope in CKD patients with hyperuricemia: a retrospective cohort study.BMC nephrology · 2026Article
- β-Carboline alkaloid harmaline alleviates hyperuricemia-mediated renal inflammation by suppressing oxidative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Gout and hyperuricemia are present in 25% and 60% of patients with chronic kidney disease (CKD), respectively. Despite the common association, the role of uric acid in the progression of kidney disease and in metabolic complications remains contested. Some authorities argue that the treatment of asymptomatic hyperuricemia in CKD is not indicated, and some have even suggested hyperuricemia may be beneficial. Here, we review the various arguments both for and against treatment. The weight of the evidence suggests asymptomatic hyperuricemia is likely injurious, but it may primarily relate to subgroups, those who have systemic crystal deposits, those with frequent urinary crystalluria or kidney stones, and those with high intracellular uric acid levels. We recommend carefully designed clinical trials to test if lowering uric acid in hyperuricemic subjects with cardiometabolic complications is protective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.